Researchers say they are close to reversing aging: the science explained

01The biology of aging and senescence

Aging is not a single process but a collection of cellular and molecular changes that accumulate over time. At its core are senescent cells — cells that have stopped dividing but refuse to die. These zombie cells secrete inflammatory molecules that damage neighbouring tissue, accelerating the decline of organs and systems.

The scientific consensus has shifted over the past two decades. Aging is no longer viewed as an inevitable entropy but as a set of biological processes that can be identified, measured, and potentially intervened upon. Researchers now speak of healthspan rather than lifespan — the goal is not merely to extend years but to compress morbidity into a shorter window at the end of life.

Nine hallmarks of aging have been catalogued, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Each represents a potential target for therapeutic intervention.

02Cellular reprogramming and Yamanaka factors

In 2006, Shinya Yamanaka identified four transcription factors — Oct4, Sox2, Klf4, and c-Myc — capable of reverting adult cells to a pluripotent stem-cell state. These Yamanaka factors earned him a Nobel Prize and opened a path that was not previously imaginable: turning back the cellular clock.

Partial reprogramming applies the Yamanaka factors for a limited duration, enough to rejuvenate cells without fully resetting them to stem cells. In animal models, this approach has reversed epigenetic age markers and restored tissue function in mice. The challenge is control — too much reprogramming produces tumours, too little has no effect.

Several biotech companies, including Altos Labs and Rejuvenate Bio, are pursuing partial reprogramming therapies. Altos Labs alone has attracted over $3 billion in funding, making it one of the best-funded private biotech endeavours in history. Human applications remain years away, but the trajectory from discovery to preclinical proof is shorter than for most drug classes.

03Senolytics clearing dead cells

Senolytics are drugs that selectively kill senescent cells. The logic is straightforward: if senescent cells cause inflammation and tissue degradation, removing them should slow aging and reduce age-related disease. In mouse studies, senolytic compounds like dasatinib and quercetin have restored physical function and extended median lifespan.

Early human trials have produced encouraging if preliminary results. A 2022 study at the Mayo Clinic showed that a senolytic cocktail improved physical function in patients with diabetic kidney disease. Other trials are targeting pulmonary fibrosis, osteoarthritis, and Alzheimer's disease — conditions where senescent cell accumulation is implicated.

The field's challenge is specificity. Current senolytics are blunt instruments, and repeated dosing could deplete beneficial cell populations. Second-generation compounds targeting specific senescence pathways are in development, but the timeline to approved therapies is measured in years, not months.

04NAD+ and mitochondrial health

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism and DNA repair. NAD+ levels decline with age — by age 50, most people have roughly half the NAD+ they had at 20. This decline impairs mitochondrial function and reduces the activity of sirtuins, proteins that regulate cellular stress responses and longevity.

Supplementation with NAD+ precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) has shown promise in animal models, restoring mitochondrial function and improving markers of metabolic health. Human trials have been mixed — NAD+ precursors appear safe and raise blood NAD+ levels, but clinical outcomes on aging endpoints are not yet demonstrated.

The broader lesson is that mitochondrial health is central to aging. Interventions that preserve mitochondrial function — whether through NAD+ supplementation, caloric restriction, or exercise — consistently produce anti-aging effects in model organisms. The mitochondria are not just the cell's power plant; they are a regulatory hub for aging biology.

05Current human trials and results

The anti-aging pipeline now includes over 200 clinical trials worldwide. The most advanced target specific age-related diseases rather than aging itself, because regulators do not recognise aging as an indication. Rapamycin, an mTOR inhibitor, is being tested in companion dogs through the Dog Aging Project, with human trials in planning.

Metformin, a diabetes drug that incidentally appears to slow aging, is the subject of the TAME (Targeting Aging with Metformin) trial — the first large-scale human study designed to test an anti-aging intervention across multiple age-related diseases. Results are expected in the late 2020s.

The distinction between treating aging and treating age-related disease is partly regulatory and partly practical. A drug that reduces cardiovascular disease, cognitive decline, and cancer risk simultaneously is effectively an anti-aging drug, even if it is approved for each condition separately. The clinical evidence is accumulating that such interventions are possible.

06The ethics of life extension

If age reversal becomes reality, the ethical implications are staggering. Life extension that adds decades of healthy life would reshape economies, pension systems, healthcare, and intergenerational dynamics. A population living to 120 or 150 would require fundamentally different social structures.

Access is the most immediate concern. Early anti-aging therapies will be expensive, available only to the wealthy, and concentrated in countries with advanced biotech infrastructure. This could create a biological divide — not just between rich and poor, but between the ageing rich who can buy more time and everyone else.

Philosophers and bioethicists debate whether indefinite life extension is desirable at all. Some argue that mortality gives life meaning and urgency. Others counter that nobody consents to the suffering of ageing and that opposing life extension is equivalent to opposing medicine itself. The debate will intensify as the science moves from speculation to capability.

07How close are we to real age reversal

The honest answer is that we are closer than ever but not yet close enough. No therapy has demonstrated age reversal in humans. What we have are promising animal studies, early-stage human trials, and a rapidly maturing scientific framework that identifies aging as a tractable problem.

The most optimistic researchers predict meaningful interventions within a decade — therapies that slow aging by several years, not reverse it entirely. The more cautious estimate 20 to 30 years before the first true age-reversal treatments reach the clinic. The difference between these estimates reflects genuine uncertainty about how quickly animal results will translate.

What is clear is that aging research has crossed a threshold. It is no longer fringe science but a well-funded, serious field with major institutions, clear targets, and accelerating progress. The question is no longer whether we can intervene on aging, but how far and how fast those interventions will go.